CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer

scientific article

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2012.42.7336
P932PMC publication ID3515767
P698PubMed publication ID23109706
P5875ResearchGate publication ID232739476

P50authorAnne-Lise Børresen-DaleQ11958220
Alison DunningQ30506457
Graham GilesQ30524411
Diether LambrechtsQ26923514
Hoda Anton-CulverQ28052887
Montserrat García-ClosasQ28356305
Gianluca SeveriQ28360445
Kamila CzeneQ28484009
Angela CoxQ28484012
Barbara BurwinkelQ28484015
Heli NevanlinnaQ29840669
Simon S. CrossQ30505778
Esther M. JohnQ59752419
Douglas F. EastonQ59812154
Paul D P PharoahQ61822938
Per HallQ62593354
Peter DevileeQ37361664
Taru A. MuranenQ37371838
Jingmei LiQ37371985
Marjanka K SchmidtQ37372106
Grethe Grenaker AlnæsQ40177166
Kelly-Anne PhillipsQ41368487
Børge G. NordestgaardQ43530123
Melissa C. SoutheyQ55446228
John HopperQ56726496
Argyrios ZiogasQ30831638
Veli-Matti KosmaQ37068464
Vesa KatajaQ37069167
Arto MannermaaQ37070123
Caroline SeynaeveQ37342673
Thilo DörkQ37342847
Vessela KristensenQ37344701
Marie-Rose ChristiaensQ87946225
Mark ShermanQ88087477
Frederik MarméQ88268377
Laura J Van't VeerQ92380286
Maren WeischerQ96185909
Manjeet K BollaQ114270702
Mitul ShahQ114292631
Mieke KriegeQ114292663
Karin LeunenQ114337516
Richard R van HienQ114337683
Fergus J. CouchQ63018779
Peter A. FaschingQ64005064
Arif B. EkiciQ64409983
Annika LindblomQ64516098
Irene L AndrulisQ64516140
Jianjun LiuQ68692572
Jonine FigueroaQ71778357
Sara MargolinQ72940025
Matthias W. BeckmannQ72940290
Stig Egil BojesenQ72992763
Carl BlomqvistQ73625505
Annegien BroeksQ73632596
Gord GlendonQ73633107
Xianshu WangQ73864709
Laura BagliettoQ74010954
Henrik FlygerQ74012148
Malcolm W. R. ReedQ74013381
Maartje J. HooningQ74014444
Natalia V. BogdanovaQ74171899
Rob TollenaarQ77085802
Julia A. KnightQ78316584
Janet E. OlsonQ78318964
P2093author name stringQin Wang
Alexander Miron
Andreas Meyer
Christof Sohn
Johanna Margriet Collée
P2860cites work‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*Q22066036
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsQ28215462
The CHEK2 gene and inherited breast cancer susceptibilityQ28265315
Chk1 and Chk2 kinases in checkpoint control and cancerQ29617706
Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor CharacteristicsQ57568345
Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying theCHEK2*1100delCGermline MutationQ61970254
Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapyQ40249058
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriersQ48002614
CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.Q51392341
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotypeQ33904762
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studiesQ33910280
Mendelian randomization: prospects, potentials, and limitationsQ34312296
CHEK2 is a multiorgan cancer susceptibility geneQ34551970
Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidenceQ35043093
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variantQ35443960
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only studyQ35794366
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controlsQ37048943
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancerQ37218535
Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?Q37225727
Increased risk of breast cancer associated with CHEK2*1100delCQ80035778
P433issue35
P407language of work or nameEnglishQ1860
P921main subjectbreast cancerQ128581
heterozygosityQ124059385
P304page(s)4308-4316
P577publication date2012-10-29
P1433published inJournal of Clinical OncologyQ400292
P1476titleCHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer
P478volume30

Reverse relations

cites work (P2860)
Q34042627AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.
Q39437211Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
Q37329388Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women
Q38776757Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study
Q90327632Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer
Q91879496Bilateral Paget's Disease of the Breast in a Patient with CHEK2 Mutation
Q35000798Biology of breast cancer in young women
Q35054455Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
Q57420847Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study
Q35180940Breast Cancer Update 2014 - Focus on the Patient and the Tumour
Q39161921Breast cancer in young women: an overview
Q34560743CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer
Q87561146Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice
Q54108246Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients.
Q47095699Clinical and genetic characterization of hereditary breast cancer in a Chinese population
Q92630618Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation
Q31118195Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks
Q26744320Contralateral prophylactic mastectomy: current perspectives
Q33911135Counselling framework for moderate-penetrance cancer-susceptibility mutations
Q33646842Estrogen signaling and the DNA damage response in hormone dependent breast cancers
Q37394076FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome
Q36915151Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
Q51764547Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Q36175072Gene-panel sequencing and the prediction of breast-cancer risk
Q37739048Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
Q64040390Genome-wide association study of germline variants and breast cancer-specific mortality
Q38780469Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
Q91525724Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico
Q38925408Hereditary breast and ovarian cancer: new genes in confined pathways
Q38266306Hereditary breast cancer syndromes and genetic testing
Q93019605High risk of breast cancer in women with biallelic pathogenic variants in CHEK2
Q40928974Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients
Q36272742Inbreeding and homozygosity in breast cancer survival
Q37378034Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model
Q34996647Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer
Q34983596Inherited predisposition to breast cancer among African American women
Q33618262Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
Q38184454Next-generation sequencing for inherited breast cancer risk: counseling through the complexity
Q30374367No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Q39160490Outcomes of retesting BRCA negative patients using multigene panels.
Q99408631Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer
Q37307937Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium
Q37131918Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families
Q41011976Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods
Q92055460Prediction and clinical utility of a contralateral breast cancer risk model
Q87933309Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples
Q92710828Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients
Q35977371Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
Q34113473Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
Q54375866Survival from breast cancer in patients with CHEK2 mutations.
Q38979257Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care
Q98293212Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer
Q52632717Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.

Search more.